<DOC>
	<DOCNO>NCT01820637</DOCNO>
	<brief_summary>To determine whether Boston Scientific nitinol drug-eluting stent show acceptable performance 9 month treat Superficial Femoral ( SFA ) and/or Proximal Popliteal Artery ( PPA ) lesion .</brief_summary>
	<brief_title>Stenting Superficial Femoral and/or Proximal Popliteal Artery Project</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subjects age 18 old Subject ( Legal Guardian applicable ) sign consent form willing able provide consent studyspecific test procedure perform agrees attend require followup visit Chronic , symptomatic low limb ischemia define Rutherford categories 2 , 3 4 Stenotic , restenotic ( angioplasty , previous treatment drug coat balloon allow ) occlusive lesion ( ) locate native superficial femoral artery proximal popliteal artery : 1 . Degree stenosis ≥70 % visual angiographic assessment 2 . Vessel diameter ≥ 4 ≤ 6mm 3 . Total lesion length ( series lesion ) ≥30 mm ≤110 mm ( Note : tandem lesion may treat , provide tandem lesion segment cover one stent ) 4 . Target lesion locate least three centimeter inferior edge femur Patent infrapopliteal popliteal artery , i.e. , single vessel runoff well least one three vessel patent ( &lt; 50 % stenosis ) ankle foot</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>SFA</keyword>
	<keyword>PPA</keyword>
	<keyword>low extremity</keyword>
	<keyword>stenting</keyword>
	<keyword>paclitaxel</keyword>
</DOC>